0001628280-20-013422.txt : 20200910 0001628280-20-013422.hdr.sgml : 20200910 20200910083544 ACCESSION NUMBER: 0001628280-20-013422 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200909 FILED AS OF DATE: 20200910 DATE AS OF CHANGE: 20200910 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ragan Paula CENTRAL INDEX KEY: 0001769914 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 201167815 MAIL ADDRESS: STREET 1: C/O X4 PHARMACEUTICALS, INC. STREET 2: 955 MASSACHUSETTS AVE., 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wf-form4_159974132949074.xml FORM 4 X0306 4 2020-09-09 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001769914 Ragan Paula C/O X4 PHARMACEUTICALS, INC. 955 MASSACHUSETTS AVENUE, 4TH FLOOR CAMBRIGE MA 02139 1 1 0 0 President and CEO Common Stock 2020-09-09 4 S 0 8840 8.04 D 287323 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.56 to $8.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units. /s/ Derek M. Meisner, attorney-in-fact 2020-09-10